The global peptide microarray market is projected to expand at a CAGR of 4.5% during the forecast period of 2023 to 2031. In the fields of proteomics and clinical assays, peptide microarrays are a robust technique for tracking the binding activity, histone-modifying enzymes, and protein linkage function on a large scale. The rising incidence of cancer and advances in technology are the primary factors driving the industry's expansion worldwide. In recent years, there has been an increase in the demand for molecular diagnostic tools due to the rise in chronic diseases. In addition, peptide microarray diagnostic tools are affordable, which drives industry expansion. The proteome-wide peptide microarray containing the COVID-19 2019-nCoV coronavirus was introduced by the company PEPperPRINT in January 2020. It is used to detect and localize IgG and IgM Abs in the serum of a patient. This is done for diagnostic tests regarding vaccine production. It is one of the factors accelerating the market and driving industry expansion.
The instruments subsegment represented a major portion of the peptide microarray market Due to technologically advanced peptide microarray products and various types of research in chronic disorders, such as cancer, autoimmune and infectious diseases, it is anticipated that the instrument segment will experience robust growth in the market and will continue to do so over the forecast period. PEPperPRIINT'sPEPperCHIP Standard Peptide Microarrays, which cover epitopes, antigens, and viral proteomics, are widely utilized in a variety of scientific fields (allergen, cancer, and signature discovery). In addition, they are utilized for antibody epitope mapping, biomarker discovery, immune monitoring, detection, and validation of protein interaction. PepStar Peptide Microarrays, manufactured by JPT Peptide Technologies, aid in enzyme profiling and identifies substrates for orphan enzymes. The research and development of peptide products are increasing because they are cost-effective, efficient, and less toxic. Nimble Therapeutics, a biotechnology company engaged in the discovery and development of peptide therapeutics, announced in September 2021 that their strategic research partnership with Incyte has been expanded to include the discovery of additional novel peptide therapies. Similarly, PEPperPRINT announced a partnership with Lucena-Chem in November 2020. Customers in Switzerland can now access PEPperCHIP Peptide Microarray products and PEPperMAP Services through Lucenna-Chem, per a new distribution agreement. Consequently, it is anticipated that such agreements will increase market growth by providing advanced instruments in the region.
These factors are anticipated to help the segment maintain its industry dominance. From 2023 to 2030, antibody characterization is expected to experience the highest growth rate. In the development of new pharmaceuticals and biosimilars, antibodies are characterized both upstream and downstream. During the early stages of drug development, characterization studies are essential for screening the correct mAb molecule by defining the critical qualitative parameters. In addition, it can be used to determine antibody type, epitope specificity, binding kinetics, cross-reactivity, and antibody affinity, thereby fostering segment expansion.
In September 2021, Nimble Medicines, a biotechnology company engaged in the discovery and production of peptide therapeutics, announced that its strategic research agreement with Incyte had been extended to include the development of additional innovative peptide therapeutics. PEPperPRINT announced a collaboration with Lucena-Chem in November 2020. A new distribution agreement gives customers in Switzerland access to PEPperCHIP Peptide Microarray products and PEPperMAP Services via Lucerna-Chem. As a result, it is anticipated that such agreements will stimulate market growth in the region by providing advanced instruments.
The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends, and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
Increasing Cancer Prevalence
Cancer's increasing prevalence and technological development is the primary forces driving the global market under study. In addition, the increasing prevalence of chronic diseases will boost the peptide microarray market. According to the International Diabetes Federation Diabetes Atlas Tenth Edition 2021, approximately 537 million adults worldwide had diabetes in 2021; this number is projected to increase to 643 million by 2030 and 785 million by 2045. The anticipated increase in diabetes incidence will increase the demand for diabetes diagnostic products and techniques, thereby driving the studied market. According to the Global Cancer Observatory (GLOBOCAN), Statistics 2020, there are an estimated 206,606,063 prevalent cases of cancer in Asia in 2020 for all types of cancer and both sexes. It also reported a 5-year prevalence of 9,738,936 cases of all types of cancer in men and 10,857,127 cases in women. Such a high prevalence of cancer in the regions generates demand for cancer treatment therapies, thereby driving the growth of the studied market. In addition, the market for peptide microarrays is dominated by the rising demand for molecular-based diagnostics techniques and the development of diagnostic testing technology. The United States Food and Drug Administration updated its definition of a biologic on February 21, 2020, to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides containing 40 amino acids or fewer. Thus, it is anticipated that the aforementioned factors will increase market growth in the future.Reimbursement Issues Constrained the Market Growth
However, reimbursement obstacles are anticipated to impede industry growth. Understanding the role of COVID-19 in the SARS-CoV-2 infection process is essential for the development of effective treatments. Proteomics is well-equipped with the necessary techniques to address this challenge. In an article published in the Journal of Proteins &Proteomics in October 2020, for instance, researchers emphasized that advances in proteome technology will not only expedite efforts to combat the coronavirus pandemic but also help to address the current COVID-19 situation.Instruments Segment Dominates the Revenue Share, while Service Segment Grows the Fastest
Based on product types, the global market is subdivided into services, instruments, and reagents. During the forecast period of 2023 and 2031, the services type segment is anticipated to experience the highest CAGR of 5%. Multiple specialized businesses provide microarray service solutions. This application may be outsourced to save time and resources while gaining access to specialized technical skills and facilities for microarray-based research diversification. These services can offer researchers the advantages of customized screening of a large number of distinct targets and markers. Consequently, it is anticipated that this will increase the demand for peptide microarrays and further boost the segment's growth.The instruments subsegment represented a major portion of the peptide microarray market Due to technologically advanced peptide microarray products and various types of research in chronic disorders, such as cancer, autoimmune and infectious diseases, it is anticipated that the instrument segment will experience robust growth in the market and will continue to do so over the forecast period. PEPperPRIINT'sPEPperCHIP Standard Peptide Microarrays, which cover epitopes, antigens, and viral proteomics, are widely utilized in a variety of scientific fields (allergen, cancer, and signature discovery). In addition, they are utilized for antibody epitope mapping, biomarker discovery, immune monitoring, detection, and validation of protein interaction. PepStar Peptide Microarrays, manufactured by JPT Peptide Technologies, aid in enzyme profiling and identifies substrates for orphan enzymes. The research and development of peptide products are increasing because they are cost-effective, efficient, and less toxic. Nimble Therapeutics, a biotechnology company engaged in the discovery and development of peptide therapeutics, announced in September 2021 that their strategic research partnership with Incyte has been expanded to include the discovery of additional novel peptide therapies. Similarly, PEPperPRINT announced a partnership with Lucena-Chem in November 2020. Customers in Switzerland can now access PEPperCHIP Peptide Microarray products and PEPperMAP Services through Lucenna-Chem, per a new distribution agreement. Consequently, it is anticipated that such agreements will increase market growth by providing advanced instruments in the region.
Diagnostics Segment Contributed to More than Half of Market Revenue in 2022
In 2022, the disease diagnostics segment led the industry and accounted for more than 55% of total revenue. The increasing complexity of chronic diseases is anticipated to increase the demand for early disease diagnosis in hospitals, resulting in an expansion of diagnostic capacities, which is anticipated to increase the use of peptide microarrays. The American Cancer Society projects that there will be 1,9 million new cancer cases and 609,360 cancer-related deaths in the United States in 2022. Cancers of the breast, lungs, prostate, and colon were the most prevalent in the United States.These factors are anticipated to help the segment maintain its industry dominance. From 2023 to 2030, antibody characterization is expected to experience the highest growth rate. In the development of new pharmaceuticals and biosimilars, antibodies are characterized both upstream and downstream. During the early stages of drug development, characterization studies are essential for screening the correct mAb molecule by defining the critical qualitative parameters. In addition, it can be used to determine antibody type, epitope specificity, binding kinetics, cross-reactivity, and antibody affinity, thereby fostering segment expansion.
Pharma and Biotech Remain the Dominant End User Segment
In 2022, the pharmaceutical and biotechnology companies segment dominated the industry and accounted for more than 55% of total revenue. From 2023 to 2030, it is anticipated that the segment will expand at a substantial rate. Numerous major corporations are investing in research and development to develop products and services for the early detection and management of chronic diseases. Consequently, organizations are adopting improved microarray technologies, which is driving the global microarray market.In September 2021, Nimble Medicines, a biotechnology company engaged in the discovery and production of peptide therapeutics, announced that its strategic research agreement with Incyte had been extended to include the development of additional innovative peptide therapeutics. PEPperPRINT announced a collaboration with Lucena-Chem in November 2020. A new distribution agreement gives customers in Switzerland access to PEPperCHIP Peptide Microarray products and PEPperMAP Services via Lucerna-Chem. As a result, it is anticipated that such agreements will stimulate market growth in the region by providing advanced instruments.
North America Remains as the Global Leader
In 2022, the North American region dominated the global industry and accounted for more than 45% of the overall revenue. The market for peptide microarrays is anticipated to be dominated by North America due to its rising healthcare expenditures and well-developed healthcare infrastructure. The increasing complexities of chronic diseases are anticipated to increase the demand for early disease diagnosis in hospitals, thereby increasing the use of diagnostic capabilities, which is anticipated to increase the use of peptide microarrays. According to Globocan 2020, the estimated incidence of new cancer cases in the United States in 2020 is 2,281,658, and the number of cancer-related deaths is 612,390. In the United States, the most prevalent cancers were breast, lung, prostate, and colon (101,809). The prevalence of cancer will increase the demand for peptide microarrays. Increasing molecular-based diagnostic techniques and rising population awareness also contribute to the expansion of the regional market. In June 2021, for instance, Nimble Therapeutics and RayzeBio announced a strategic partnership to discover and develop novel peptide-based radiopharmaceuticals for the treatment of cancer. Analysts anticipate that generic versions of Advair, Revlimid, and Abraxane will be introduced in the United States during Cipla's fiscal year 2023, as announced in May 2021. Partnered filings for injectable peptides also enhance pipeline opportunities. Consequently, such an expanding product pipeline in the region is anticipated to stimulate market expansion. On the other hand, the Asia-Pacific region is anticipated to experience the highest growth rate over the forecast period, owing to increased government support in the healthcare industry, high awareness about antibody-based research, and expansion of proteomics in the region. The prevalence of chronic diseases has increased in Indonesia, and the rising demand for rapid and accurate diagnosis can be met by microarrays, which will further propel market growth in the Asia-Pacific region.Market Competition to Intensify During the Forecast Period
The market for peptide microarrays is moderately competitive and comprises several major players. Merck KGaA, ProImmune Ltd, JPT Peptide Technologies, Terra Universal Inc., and Arrayit Corporation, among others, currently dominate the market. Multiple end-users' ongoing demand for peptide microarray solutions has created numerous growth opportunities for industry participants. In June 2022, for instance, Ariceum Therapeutics raised EUR 25 million in Series A funding to enhance its lead asset, Satoreotide, for the diagnosis of low- and high-grade neuroendocrine cancers.Historical & Forecast Period
This study report represents an analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends, and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. A key data point that enables the estimation of the Peptide Microarrays market is as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- A number of end users and consumption volume, price, and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Peptide Microarrays market and their expected impact during the forecast period.
Market Segmentation
Type
- Instruments
- Reagents
- Services
Application
- Disease Diagnostics
- Protein Functional Analysis
- Antibody Characterization
- Drug discovery
End-user
- Pharmaceutical & Biotechnology Companies
- Hospitals & Clinics
- Diagnostic Centers
- Others
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of the Peptide Microarrays market?
- What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2031.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Peptide Microarrays market?
- Which is the largest regional market for the Peptide Microarrays market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Peptide Microarrays market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Peptide Microarrays market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Peptide Microarrays Market
2.2. Global Peptide Microarrays Market, By Type, 2022 (US$ Million)
2.3. Global Peptide Microarrays Market, By Application, 2022 (US$ Million)
2.4. Global Peptide Microarrays Market, By End-user, 2022 (US$ Million)
2.5. Global Peptide Microarrays Market, By Geography, 2022 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2022
3. Peptide Microarrays Market: Competitive Analysis
3.1. Market Positioning of Key Peptide Microarrays Market Vendors
3.2. Strategies Adopted by Peptide Microarrays Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2022 Versus 2031
4. Peptide Microarrays Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Peptide Microarrays Market Value, 2021 - 2031, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2022 Versus 2031
5.3. Market Segmentation
5.3.1. Instruments
5.3.2. Reagents
5.3.3. Services
6. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2022 Versus 2031
6.3. Market Segmentation
6.3.1. Disease Diagnostics
6.3.2. Protein Functional Analysis
6.3.3. Antibody Characterization
6.3.4. Drug discovery
7. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2022 Versus 2031
7.3. Market Segmentation
7.3.1. Pharmaceutical & Biotechnology Companies
7.3.2. Hospitals & Clinics
7.3.3. Diagnostic Centers
7.3.4. Others
8. North America Peptide Microarrays Market, 2021-2031, USD (Million)
8.1. Market Overview
8.2. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
8.3. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
8.4. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
8.5.Peptide Microarrays Market: By Region, 2021-2031, USD (Million)
8.5.1.North America
8.5.1.1. U.S.
8.5.1.1.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
8.5.1.1.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
8.5.1.1.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
8.5.1.2. Canada
8.5.1.2.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
8.5.1.2.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
8.5.1.2.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
8.5.1.3. Rest of North America
8.5.1.3.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
8.5.1.3.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
8.5.1.3.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
9. UK and European Union Peptide Microarrays Market, 2021-2031, USD (Million)
9.1. Market Overview
9.2. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
9.3. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
9.4. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
9.5.Peptide Microarrays Market: By Region, 2021-2031, USD (Million)
9.5.1.UK and European Union
9.5.1.1. UK
9.5.1.1.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
9.5.1.1.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
9.5.1.1.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
9.5.1.2. Germany
9.5.1.2.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
9.5.1.2.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
9.5.1.2.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
9.5.1.3. Spain
9.5.1.3.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
9.5.1.3.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
9.5.1.3.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
9.5.1.4. Italy
9.5.1.4.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
9.5.1.4.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
9.5.1.4.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
9.5.1.5. France
9.5.1.5.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
9.5.1.5.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
9.5.1.5.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
9.5.1.6. Rest of Europe
9.5.1.6.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
9.5.1.6.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
9.5.1.6.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
10. Asia Pacific Peptide Microarrays Market, 2021-2031, USD (Million)
10.1. Market Overview
10.2. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
10.3. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
10.4. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
10.5.Peptide Microarrays Market: By Region, 2021-2031, USD (Million)
10.5.1.Asia Pacific
10.5.1.1. China
10.5.1.1.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
10.5.1.1.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
10.5.1.1.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
10.5.1.2. Japan
10.5.1.2.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
10.5.1.2.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
10.5.1.2.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
10.5.1.3. India
10.5.1.3.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
10.5.1.3.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
10.5.1.3.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
10.5.1.4. Australia
10.5.1.4.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
10.5.1.4.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
10.5.1.4.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
10.5.1.5. South Korea
10.5.1.5.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
10.5.1.5.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
10.5.1.5.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
10.5.1.6. Rest of Asia Pacific
10.5.1.6.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
10.5.1.6.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
10.5.1.6.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
11. Latin America Peptide Microarrays Market, 2021-2031, USD (Million)
11.1. Market Overview
11.2. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
11.3. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
11.4. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
11.5.Peptide Microarrays Market: By Region, 2021-2031, USD (Million)
11.5.1.Latin America
11.5.1.1. Brazil
11.5.1.1.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
11.5.1.1.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
11.5.1.1.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
11.5.1.2. Mexico
11.5.1.2.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
11.5.1.2.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
11.5.1.2.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
11.5.1.3. Rest of Latin America
11.5.1.3.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
11.5.1.3.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
11.5.1.3.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
12. Middle East and Africa Peptide Microarrays Market, 2021-2031, USD (Million)
12.1. Market Overview
12.2. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
12.3. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
12.4. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
12.5.Peptide Microarrays Market: By Region, 2021-2031, USD (Million)
12.5.1.Middle East and Africa
12.5.1.1. GCC
12.5.1.1.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
12.5.1.1.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
12.5.1.1.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
12.5.1.2. Africa
12.5.1.2.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
12.5.1.2.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
12.5.1.2.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
12.5.1.3. Rest of Middle East and Africa
12.5.1.3.1. Peptide Microarrays Market: By Type, 2021-2031, USD (Million)
12.5.1.3.1. Peptide Microarrays Market: By Application, 2021-2031, USD (Million)
12.5.1.3.1. Peptide Microarrays Market: By End-user, 2021-2031, USD (Million)
13. Company Profile
13.1. Merck KGaA
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Portfolio
13.1.4. Strategic Initiatives
13.2. ProImmune Ltd
13.2.1. Company Overview
13.2.2. Financial Performance
13.2.3. Product Portfolio
13.2.4. Strategic Initiatives
13.3. JPT Peptide Technologies
13.3.1. Company Overview
13.3.2. Financial Performance
13.3.3. Product Portfolio
13.3.4. Strategic Initiatives
13.4. Terra Universal Inc.
13.4.1. Company Overview
13.4.2. Financial Performance
13.4.3. Product Portfolio
13.4.4. Strategic Initiatives
13.5. Arrayit Corporation
13.5.1. Company Overview
13.5.2. Financial Performance
13.5.3. Product Portfolio
13.5.4. Strategic Initiatives
13.6. Others
13.6.1. Company Overview
13.6.2. Financial Performance
13.6.3. Product Portfolio
13.6.4. Strategic Initiatives
List of Figures
Figure 1 Global Peptide Microarrays Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Peptide Microarrays Market: Quality Assurance
Figure 5 Global Peptide Microarrays Market, By Type, 2022
Figure 6 Global Peptide Microarrays Market, By Application, 2022
Figure 7 Global Peptide Microarrays Market, By End-user, 2022
Figure 8 Global Peptide Microarrays Market, By Geography, 2022
Figure 9 Market Geographical Opportunity Matrix - Global Peptide Microarrays Market, 2022
Figure 10 Market Positioning of Key Peptide Microarrays Market Players, 2022
Figure 11 Global Peptide Microarrays Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
Figure 12 Global Peptide Microarrays Market, By Type, 2022 Vs 2031, %
Figure 13 Global Peptide Microarrays Market, By Application, 2022 Vs 2031, %
Figure 14 Global Peptide Microarrays Market, By End-user, 2022 Vs 2031, %
Figure 15 U.S. Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 16 Canada Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 17 Rest of North America Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 18 UK Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 19 Germany Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 20 Spain Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 21 Italy Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 22 France Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 23 Rest of Europe Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 24 China Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 25 Japan Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 26 India Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 27 Australia Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 28 South Korea Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 29 Rest of Asia Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 30 Brazil Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 31 Mexico Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 32 Rest of Latin America Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 33 GCC Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 34 Africa Peptide Microarrays Market (US$ Million), 2021 - 2031
Figure 35 Rest of Middle East and Africa Peptide Microarrays Market (US$ Million), 2021 - 2031
List of Figures
Table 1 Global Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 2 Global Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 3 Global Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 4 North America Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 5 North America Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 6 North America Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 7 U.S. Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 8 U.S. Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 9 U.S. Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 10 Canada Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 11 Canada Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 12 Canada Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 13 Rest of North America Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 14 Rest of North America Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 15 Rest of North America Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 16 UK and European Union Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 17 UK and European Union Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 18 UK and European Union Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 19 UK Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 20 UK Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 21 UK Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 22 Germany Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 23 Germany Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 24 Germany Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 25 Spain Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 26 Spain Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 27 Spain Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 28 Italy Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 29 Italy Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 30 Italy Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 31 France Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 32 France Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 33 France Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 34 Rest of Europe Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 35 Rest of Europe Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 36 Rest of Europe Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 37 Asia Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 38 Asia Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 39 Asia Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 40 China Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 41 China Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 42 China Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 43 Japan Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 44 Japan Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 45 Japan Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 46 India Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 47 India Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 48 India Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 49 Australia Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 50 Australia Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 51 Australia Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 52 South Korea Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 53 South Korea Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 54 South Korea Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 55 Latin America Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 56 Latin America Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 57 Latin America Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 58 Brazil Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 59 Brazil Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 60 Brazil Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 61 Mexico Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 62 Mexico Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 63 Mexico Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 64 Rest of Latin America Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 65 Rest of Latin America Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 66 Rest of Latin America Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 67 Middle East and Africa Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 68 Middle East and Africa Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 69 Middle East and Africa Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 70 GCC Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 71 GCC Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 72 GCC Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 73 Africa Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 74 Africa Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 75 Africa Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Table 76 Rest of Middle East and Africa Peptide Microarrays Market By Type, 2021-2031, USD (Million)
Table 77 Rest of Middle East and Africa Peptide Microarrays Market By Application, 2021-2031, USD (Million)
Table 78 Rest of Middle East and Africa Peptide Microarrays Market By End-user, 2021-2031, USD (Million)
Companies Mentioned
- Merck KGaA
- ProImmune Ltd
- JPT Peptide Technologies
- Terra Universal Inc.
- Arrayit Corporation
